SynDermix is a Swiss clinical-stage biotechnology company that develops leading-edge treatments in areas of unmet medical need. Powered by three platform technologies and defined by synergism, our focus is on frontier pipeline candidates that target disorders affecting the epithelial tissues of the human body and which improve their well-being.
SynDermix drives a lectin pipeline which uses state-of-the-art recombinant DNA technology to harness the carbohydrate-binding specificities of plant lectins to inhibit pathogenic processes in host cells.
Our nitric oxide pipeline combines a proprietary formulation and an innovative medical device to achieve clinical proof of concept in various dermatological indications.
We are leveraging biomedical engineering for the application of localised vibration to significantly alleviate the troublesome chronic symptoms of clinical conditions with currently no satisfactory standard of care.
Together, our executive team, specialist partners and company values combine to sustain ground-breaking health science and process excellence.
Our news and media pages provide information on our latest developments, as well as access to our press releases, company fact-sheet and presentation.
SynDermix is a private company and is in preparation to list on the SIX Swiss Stock Exchange. Investors and other account holders, please click here to log in.
